As the RNA solutions leader for academic research and therapeutic development, Eclipsebio is dedicated to sponsoring events that bring together world experts in RNA biology and therapeutics. Eclipsebio is proud to announce our sponsorship of the Mechanisms of RNA Decay meeting. The meeting will be held in Lisbon, from August 18 to August 22. This conference will feature discussions on:
- Methods for studying RNA decay
- The process of RNA decay across organisms
- Aspects of RNA decay mechanisms, including the relationship between degradation and translation
We are looking forward to supporting the exciting exchange of ideas and career development opportunities that this meeting offers.
If you are interested in making your own discoveries with our comprehensive solutions for therapeutic development or academic research, contact our team of RNA experts today.
Latest news
Eclipsebio Expands eMERGE™ Platform with eSENSE dsRNA™ for dsRNA Quantification and Localization
SAN DIEGO, September 3, 2024 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in developing precision solutions for RNA-based and RNA-targeting therapeutics, today announced the launch of its eSENSE dsRNA™ assay. eSENSE dsRNA is a next-generation sequencing method for the robust quantification, localization, and optimization of double-stranded RNA (dsRNA) contaminants in RNA-based vaccines and therapeutics. “By […]
RNA and AI Symposium 2024
Eclipsebio is proud to announce their sponsorship of RNA UK 2024, the premier event for bringing experts in RNA biology together to discuss the latest RNA discoveries.
Mechanisms of RNA Decay 2024
Eclipsebio is proud to announce their sponsorship of RNA UK 2024, the premier event for bringing experts in RNA biology together to discuss the latest RNA discoveries.
Eclipsebio Launches eMERGE™ Platform, a Cutting-Edge End-to-End Solution for the Characterization and Optimization of RNA-Based Therapeutic Products
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGE™ platform.